Cancer Cachexia Market Analysis

Mode of Action (Weight Loss Stabilizers, Appetite Stimulants)

The weight loss stabilizers segment in the cancer cachexia market is anticipated to hold the largest share of about 55% during the forecast period. Because cancer patients experience extreme weight loss, weight loss stabilizers dominate the market for cancer cachexia. Physicians offer weight loss stabilizers to counteract weight loss and improve the quality of life for cancer patients experiencing cachexia. Cytokine inflammation, tissue loss, wasting syndrome, and cystic fibrosis are the hallmarks of cachexia. To enhance the quality of life for cancer patients, it is imperative to counteract weight loss in this condition. Cachexia results from uncontrollably losing muscle mass, dying from radiation and chemotherapy, and seeing an 85% increase in the last one to two weeks. Furthermore, as the condition progresses, 45% of patients lose more than 10% of their initial weight. Weight stabilizers are advised by doctors to prevent cachexia.

Drugs (Progestogens, Dronabinol, Mega Sterol Acetate, Corticosteroids)

The progestogens segment is expected to hold 48% share of the cancer cachexia market by 2036. The primary reasons for this are progestogen's cost-effectiveness, tolerability, and efficacy in treating cachexia. Since progestogens are more effective than other medications, it is anticipated that demand for them will stay high over the coming years. In addition to these, the most efficient and painless treatment for cancer cachexia was progestogens. As a result, it will still be significant in the progestogens market sector. The goals of the current treatments are cancer cachexia palliation as well as patient and family relief.

Our in-depth analysis of the global cancer cachexia market includes the following segments: